Israeli healthtech VC aMoon Velocity invests $6 million in Nectin Therapeutics

Nectin Therapeutics places antibodies in proteins known to cause cancer, improving immune systems and blocking certain checkpoints

James Spiro 13:1715.07.20
Israel’s largest healthtech venture fund, aMoon, announced an investment of $6 million in Nectin Therapeutics Ltd. via its early-stage fund, aMoon Velocity. Integra Holdings, an existing investor exclusively focused on life sciences from The Hebrew University of Jerusalem also participated in the financing round. The total funding is expected to reach $15 million.


Nectin family of proteins enables many cancers to evade detection and attack the immune system. Nectin Therapeutics develops novel monoclonal antibodies that inhibit the activity of the Nectin proteins and therefore boost the immune system and help it fight cancers in solid tissue and in the bloodstream.

Nectin and aMoon teams. Photo: aMoon Fund Nectin and aMoon teams. Photo: aMoon Fund


Human bodies can detect and destroy certain cancer cells already, but many others have intense defense mechanisms against immune systems. Nectin Therapeutics helps block certain immune checkpoints, advancing cancer therapies, and potentially saving patients’ lives.



Dr. Pini Tsukerman, Co-Founder and Chief Scientist at Nectin Therapeutics, believes the procedure has the potential to help cancer patients around the world: “Our expertise combines in-depth understanding of the evasion mechanisms of cancerous tumors from identification by the immune system together with extensive immunological knowledge. We are currently in advanced development stages of a number of antibodies that can improve therapeutic offerings for cancer patients.”


“We believe that new immune checkpoint inhibitors will significantly enrich the toolbox of immunotherapy treatments and enable a more effective fight against cancer, whether as an independent treatment or in combination with existing approved drugs,” added Dorit Sokolov, Managing Director at aMoon Velocity.